CERVICAL SCREENING UPDATE
|
|
- Madison Brooks
- 5 years ago
- Views:
Transcription
1 CERVICAL SCREENING UPDATE Louise Cadman Research Nurse Consultant and Nurse Colposcopist Centre for Cancer Prevention Wolfson Institute of Preventive Medicine
2 Learning Objectives State the objectives of the cervical screening programme Identify the principles of screening programmes Explain the way the cervical screening programme operates in the UK Understand the prevalence of cervical screening abnormalities Manage cervical screening results correctly Explain colposcopy to a patient
3 The aim of the NHS Cervical Screening Programme is to reduce the number of women who develop cervical cancer and the number of women who die from the condition NHS Choices
4 Principles of screening programmes
5 Wilson and Jungner classic screening criteria, WHO Condition should be an important health problem 2. Accepted treatment for recognised disease 3. Facilities for diagnosis and treatment should be available 4. Recognisable latent or early symptomatic stage 5. Suitable test or examination 6. Test acceptable to the population 7. Natural history of the condition should be adequately understood 8. Agreed policy on whom to treat as patients 9. Cost of screening, diagnosis and treatment economically viable 10. Case-finding a continuing process Wilson. JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO; Available from:
6 Cervical cancer the size of the problem
7 Worldwide cervical cancer incidence 2012 fourth most common cancer worldwide for females seventh most common cancer overall >527,000 new cases diagnosed 266,000 deaths 85% in the developing world
8 The 20 most common cancers in women, 2011 Number of New Cases, UK Breast Lung Bowel Other Sites Uterus Ovary Malignant Melanoma Non-Hodgkin Lymphoma Brain, Other CNS & Intracranial Tumours Pancreas Kidney Leukaemia Cervix Bladder Oesophagus Stomach Oral Myeloma Thyroid Liver 12 th most common cancer amongst females in the UK 2851 cases/year 972 deaths/year 67% survived five years ( ) 0 10,000 20,000 30,000 40,000 50,000
9 Age-specific incidence rates and number of cases diagnosed by five year age group, England in 10 of all new cases of cervical cancer are diagnosed in women under 50 years
10 per 100,000 European Age-Standardised Cervical Cancer Incidence & Mortality Rates per 100,000 Female Population, UK Incidence Mortality Prepared by Cancer Research UK Original data sources: Office for National Statistics. Cancer Statistics: Registrations Series MB1. Welsh Cancer Intelligence and Surveillance Unit. Information Services Division Scotland. Cancer Information Programme. Year
11 Per 100, European age-standardised incidence rates of cervical cancer per 100,000 female population, by age in UK to to to to to Years
12 Number of cases by morphology, England Squamous Adenocarcinoma Unclassified Epithelial Adenosquamous Neuroendocrine 1000 Other Epithelial Other Year of Diagnosis
13 Cervical screening as secondary prevention of cervical cancer Cervical screening morbidity mortality! Limitations: does not prevent: oncogenic HPV infection precursor lesions (high grade Cervical Intraepithelial Neoplasia (CIN)) less efficient for early stages of adenocarcinoma screening programmes not achievable in many countries may not detect lesions which progress quickly in time only effective if women attend regularly, when invited
14 NHS Cervical Screening Programme Coverage
15 Five year coverage of the target age group (25-64), Primary Care Organisation, England, 31 st March 2013 Source: KC53, Health and Social Care Information Centre.
16 Cervical screening coverage by London Primary Care Organisation, (% less than 5 years since last adequate test) Kensington & Chelsea PCT Richmond & Twickenham PCT Tower Hamlets PCT Hillingdon PCT Brent Teaching PCT Haringey Teaching PCT Barnet PCT Hammersmith & Fulham PCT Croydon PCT Islington PCT Ealing PCT Lewisham PCT Newham PCT Bromley PCT Lambeth PCT Barking & Dagenham PCT Harrow PCT Redbridge PCT Enfield PCT Sutton & Merton PCT Waltham Forest PCT Bexley Care Trust Southwark PCT Hounslow PCT Kingston PCT Camden PCT Westminster PCT Wandsworth PCT City & Hackney Teaching PCT Havering PCT Greenwich Teaching PCT %
17 % NHS Cervical Screening Programme, : coverage-less than 5 years (%)
18 Five year coverage of the target age group (25-64) England at 31 st March, 2003 to 2013 Data prior to 2005, re-used with the permission of the Department of Health. Source: KC53, Health and Social Care Information Centre.
19 Anatomy of the cervix
20 Uterus Upper body Cervix Cervix Cylindrical ~ 3cm length ~ 2.5cm diameter 1/3 protrudes into the vaginal vault Os the hole Ectocervical = outside the external os Endocervical = inside cervical canal The Uterine Cervix
21 Stratified squamous epithelium
22 Columnar epithelium
23 Squamo-columnar junction (SCJ)
24 Cervical Epithelium Squamous epithelium Usually on ectocervix Cells are multilayered Usually appears as smooth, shiny, pale pink Columnar epithelium Mostly endocervical Single layer column shaped cells Delicate and usually appears red (ectopy when on ectocervix) Squamo-columnar junction (SCJ)
25 Transformation zone
26 Types of Transformation Zone Type I TZ completely ectocervical and fully visible Type II TZ partially endocervical but fully visible Type III TZ endocervical and not fully visible
27 HPV Infection in the Cervix HPV infects cell integrates its DNA into the host cell DNA Persistence cell damage (pre-cancer) Eventually cancer Normal Epithelium HPV Infection CIN I CIN II CIN III Cancer Months Years Decades
28 Dyskaryosis identified by cytology
29 CIN 1 CIN 2 CIN 3
30 Screening intervals and sample taking
31 Screening Intervals in England 25 years - first invitation from GP lists invitation should not be before age 24.5 years years - three yearly years - five yearly 65+ years - only screen those not screened since age 50 or with recent abnormal tests
32 Summary percentage preventable by 3- and 5-yearly screening Annual 3 yearly 5 yearly years 76% 61% 30% (39%) years 88% 84% 73% years 87% 87% 83% * The percentage in parentheses is obtained by replacing RRs greater than one with 1.0 when averaging Benefit of cervical screening at different ages: evidence from the UK audit of screening histories P Sasieni, J Adams and J Cuzick British Journal of Cancer (2003) 89,
33 Samples examined by source of sample,
34 In women who are heavy cigarette smokers On taking or starting to take an oral contraceptive On insertion of an IUCD or IUS In women who have had multiple sexual partners In women with pelvic infection Additional cervical screening is not justified in any of the following situations providing the woman has undergone screening within the previous three to five years and is on routine recall: On starting or taking HRT Antenatally, postnatally or after termination of pregnancy In women with vaginal discharge In women with genital warts
35 Be realistic in the length of time it should take This should not take longer than five minutes but I will keep you informed You are unlikely to be able to relax but try to avoid lifting your bottom off the couch Would you like to empty your bladder before we start? Prior to the examination Please indicate if you would like to stop and I will be guided by you Some women may wish to agree a non-verbal sign You may experience some discomfort but let me know if it is unbearable 35 Avoid the word relax! Would you like to have anyone else in the room with us? Would you like me to tell you what I am doing as we go along? Some women prefer it if you just get on with it
36 Taking a sample Wash hands and wear gloves. Close the speculum before starting and then gently insert into the vagina and aim for the posterior vault Open the blades approximately 5mm and guide speculum until the anterior lip of cervix can be seen. Only open the speculum wide enough to reveal the whole cervix Do not over-expose the cervix and vagina as this may cause discomfort to the woman If you cannot visualise the cervix, consider repositioning the woman by raising her hips, adjust the speculum rotating it so locking ratchet faces up or down or using a condom to support vaginal walls Inspect the cervix; noting appearance, colour, amount and colour of vaginal secretions and the location of the transformation zone Obtain the sample using the appropriate sampling device ensuring all the transformation zone is sampled and ensure sample placed in LBC vial as per protocol Remove speculum it may be necessary to open it slightly first to release the cervix before removing it and ensure safe disposal of all equipment in accordance with local health and safety guidelines
37 Following the examination If you cannot visualise the cervix, and nor can any colleague you ask to assist, then the procedure should be abandoned and referral made to a colposcopy clinic Ensure that the woman knows how and when she will receive her results. Complete the sample request form accurately Explain that spotting following the test is possible and to be expected If additional tests or swabs were taken these should be discussed and arrangements made for her to receive these results and any follow-up treatment Reassurance should be given about what will happen if a result is abnormal and what will happen next From: Cervical screening - RCN guidance for good practice
38 Results and referral to colposcopy
39 Results of adequate tests for women aged 25-64, Total number of results: 3,283, % of reports authorised within 0-2 weeks (0-14 days) 0.2% of reports authorised within 3-4 weeks (15-28 days)
40 % Cytology results by region and Primary Care Trust, Severe dyskaryosis or worse Moderate dyskaryosis Mild dyskaryosis Borderline changes Negative
41 Summary of referral/waiting time standards Cytology/HPV NHSCSP standard 3 consecutive inadequate samples Offered an appointment Borderline change or low grade / HR-HPV positive with a colposcopist within 6 weeks High-grade (moderate) or high-grade (severe)? Invasive squamous carcinoma? Glandular neoplasia of endocervical type or not otherwise specified? Glandular neoplasia cells of other origin referral outside NHSCSP Abnormal cervix (outside the NHSCSP) Symptomatic (outside NHSCSP) Offered an appointment with a colposcopist within 2 weeks Offered an appointment with a gynaecologist within 2 weeks
42 Direct referral for colposcopy Smear taker referral for colposcopy Sample taken Sample taken Sample taker receives results and made aware of direct referral Sample processed and cytology results available Direct referral from laboratory to colposcopy Sample processed and cytology results available Sample taker receives results and refers to colposcopy Referral from GP to colposcopy. Patient sent appointment Colposcopy Programme and Management Guidelines (2010) state that: At least 90% of women with an abnormal test should be seen in a colposcopy clinic within 8 weeks of referral and that at least 90% of women with a test result of moderate or severe dyskaryosis should be seen within 4 weeks
43 Test of Cure After treatment for all grades of CIN women invited for cervical cytology at 6 months Negative, borderline change or low-grade dyskaryosis => HR-HPV test HPV negative => screening test in three years (irrespective of age) => returned to routine recall if the subsequent test negative; HPV positive => referred back to colposcopy. Cytology high grade or worse => straight to colposcopy
44
45 COLPOSCOPY Louise Cadman Research Nurse Consultant and Nurse Colposcopist Centre for Cancer Prevention Wolfson Institute of Preventative Medicine
46 Aims of Colposcopy To determine extent of the lesion Visualise the entire squamocolumnar or the colposcopy is unsatisfactory. Identify the transformation zone (TZ). Obtain directed biopsies from abnormal/- suspicious areas To confirm nature of lesion and to rule out invasion
47 Colposcopy A specialist technique Gives a magnified image of the cervix Solutions applied which reveal changes in the epithelium 5% acetic acid Iodine
48 Colposcopic signs MARGINS COLOUR IODINE VESSELS
49 Normal Colposcopy with acetic acid with iodine
50 CIN I with acetic acid with iodine
51 Percent Procedure at colposcopy by reason for referral (N=3,320,389) Other Ablation with biopsy Ablation without biopsy Excision Diagnostic biopsy No procedure 0 All referrals Inadequate Low Grade High Grade Reason for referral Clinical Indication - Urgent Clinical Indication - Non urgent
52 Treatment Methods
53 Large Loop Excision of the Transformation Zone - LLETZ
54 Large Loop Excision of the Transformation Zone - LLETZ
55 LLETZ Local anaesthetic Cuts blocks up to 1.5 cm deep Provides a specimen for histology Good haemostasis Quick and simple Little thermal damage to cervix or specimen
56 Cold coagulation Heats superficial tissues to 100 C Suitable for small lesions / low grade CIN Rapid (20 seconds per field)
57 Cryocautery Freezes using nitrous oxide Treatment ablates affected area Treats to a depth of 4 mm
58 LASER Light Amplification Stimulated Emission of Radiation
59 Cold knife cone biopsy
60 Depth/length of excision Type I TZ: 7mm (95%) aim to remove <10 mm in women of reproductive age Type II TZ: 10-15mm, depending on the position of the scj within endocervical canal. When Type I or II (for CIN) 15mm (85%) Type III TZ: 15-25mm
61 Information for women after outpatient treatment Avoid tampons for four weeks Abstain from vaginal intercourse for four weeks Avoid swimming for two weeks May consume alcohol in moderation after treatment Other normal activities, including light exercise, may continue Although there are no known health grounds for avoiding travel following treatment problems may not be covered by insurance May be a temporary change in menstrual pattern Single excision <10mm not associated with any increased incidence of preterm labour and preterm pre-labour rupture of membrane Single excision not associated with any increased risk of infertility but may increase the risk of mid-trimester miscarriage.
62 Future developments
63 Prophylactic Vaccines Gardasil (Sanofi Pasteur MSD) Quadrivalent HPV types 6,11,16 and 18 Adjuvant aluminium salts Bivalent Cervarix (GSK) HPV types 16 and 18 Adjuvant ASO4 UK vaccination programme introduced in September 2008
64 Recent results for HPV prevalence in England Previous calculation: number of cancers could be reduced to cytology screening samples + pathology samples HPV 16 and 18 found in 76.4% of squamous cell cancers 81.9% of adenocarcinomas 63% of CIN 3 91% of high grade glandular lesions Frequently found multiple HPV types in a lesion Number of cancers could be reduced to 700 Howell-Jones R, et al Br J Cancer 2010:103;209-16; doi: /sj.bjc
65 Monitoring after vaccination Monitoring essential: type-specific HPV tests needed Duration of protection years? booster needed? Relevance of antibody levels Detection of non-vaccine HPV types Cuzick J, et al. Vaccine 2008; 26S:K29 K41 Fraser C, et al. Vaccine. 2007; 25: David MP, et al. Gynecol Oncol. 2009
66 Screening in the era of vaccination: challenges and possibilities HPV as primary screen? Increase screening interval to?5 years Transience of infection At what age to start? Maybe age 30? Triage using cytology? When to refer for colposcopy? Median duration time of HPV infection Tampon (months) Any 9.8 hrhpv 9.3 lrhpv Swab Vaginal washings Brush
67 New developments Nonavalent human papillomavirus (HPV) vaccine, including HPV-types 6/11/16/18/31/33/45/52/58 Therapeutic vaccine: ProCervix - bivalent HPV 16 and 18 therapeutic vaccine
68 Useful websites
Scottish Cervical Screening Programme. Colposcopy and Programme Management
Scottish Cervical Screening Programme Colposcopy and Programme Management Addendum to NHSCSP Publication No 20 Second Edition Exceptions Applicable in NHS Scotland April 2013 (Final Version 2.8 to incorporate
More informationPap test results FOR WOMEN WITH AN ABNORMAL PAP TEST
Pap test results FOR WOMEN WITH AN ABNORMAL PAP TEST Introduction This booklet provides women with information about abnormal Pap test results. Many women feel anxious or worried when they are told their
More informationCervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
More informationCytology Update M Laing QEUH
Cytology Update M Laing QEUH Age change to 25 to 65 Age 25 to 50 Three yearly smear invitation Age 50 to 65 Five yearly smear invitation Women on non routine screening will be invited up to age 70 OUTCOME
More informationNHS cervical screening Helping you decide
NHS cervical screening Helping you decide What is cervical cancer? 2 What causes cervical cancer? 2 What is cervical screening? 3 Cervical screening results 6 What is a colposcopy? 8 Making a choice the
More informationColposcopic Principles. Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK
Colposcopic Principles Simon Leeson Consultant Obstetrician/ Gynaecologist Betsi Cadwaladr University Health Board UK The cervix topics discussed are: original squamous epithelium endocervical epithelium
More informationInternational Federation of Gynecology and Obstetrics
International Federation of Gynecology and Obstetrics Treatment of Cervical Precancerous Lesions using Thermocoagulation(Cold Coagulation) and Cryotherapy General Principles All high grade CIN should be
More informationInformation on: Cervical. screening. (smear test) jostrust.org.uk
Information on: Cervical screening (smear test) jostrust.org.uk Cervical screening This booklet covers: What is cervical screening? Who is eligible for screening? What happens when I have a screening sample
More informationAccess to dental services and oral health for residents in the borough of Barnet
Appendix 1 Access to dental services and oral health for residents in the borough of Barnet Dental access for children resident in Barnet is slightly higher than the London average, but lower than that
More informationCERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)
CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) The cervix constitutes the lower third of the uterus. It is in two parts, the endocervix and the ectocervix. Ectocervix is covered with squamous epithelium. Endocervix
More informationCervical Skills. Dr Margaret Laing Queen Elizabeth University Hospital
Cervical Skills Dr Margaret Laing Queen Elizabeth University Hospital What is screening? Screening is a test offered to an apparently well person with the possibility of detecting a serious disease before
More informationGUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) Approved by Guidelines Assessment Panel
NORFOLK & WAVENEY CELLULAR PATHOLOGY SERVICE GUIDELINES FOR CERVICAL CYTOLOGY SPECIMENS CA1066 (V8) DEPT. SOP NO.:C.SC.I.806b EDITION: 8 AUTHORISED BY: See table below AUTHOR: VIKI FREW DATE OF ISSUE:
More informationCervical Conization. 1
Cervical Conization www.zohrehyousefi.com 1 Cone Biopsy is a surgical procedure with removal of a cone shaped portion of the cervix The extent of involvement of epithelium on the ectocervix has been clearly
More informationcle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil BJMP 2008:1(2) 18-22
BJMP 2008:1(2) 18-22 Review Articl cle Modern management of abnormal cervical smear Tint Tint Wai and Dilip Patil Abbreviations BSCCP British Society of Colposcopy and Cervical Pathology CIN Cervical intraepithelial
More informationYou have been asked to come for a Colposcopy examination because your cervical screening test (smear) has shown evidence of abnormal cells.
Colposcopy Examination One Stops Patient Information Sheet Why do I need a Colposcopy examination at the one stop clinic? You have been asked to come for a Colposcopy examination because your cervical
More informationInformation on: Cervical. screening. (smear test) jostrust.org.uk
Information on: Cervical screening (smear test) jostrust.org.uk Cervical screening This booklet covers: What is cervical screening? Who is eligible for screening? What happens when I have a screening sample
More informationNorthern Ireland Cervical Screening Programme
Northern Ireland Cervical Screening Programme ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 1 Report produced by : Quality Assurance Reference Centre, PHA Date of Publication: September 2012 2 Contents
More informationDiabetes in London. Dr Jane Fryer. Date
Diabetes in London Date Dr Jane Fryer Diabetes Senior Responsible Officer, NHE England - London Region Medical Director, South London, NHS England London Region December 2017 London Regional Diabetes Event
More informationLONDON BOROUGH OF HAVERING
LONDON BOROUGH OF HAVERING Alcohol Briefing Note 2018 Mortality, Admissions and Ambulance Dispatches Locality and Ward Level Insights By Public Health Intelligence London Borough of Havering 1 Information
More informationBreast Screening Data Stephen Scott Head of Informatics LCA
Breast Screening Data Stephen Scott Head of Informatics LCA stephenscott@nhs.net The London Cancer Alliance Overview 62 day screening to 1 st treatment performance Key surgical measures monitored by LCA
More informationA Guide To Understanding Your Cervical Screening Test Results
A Guide To Understanding Your Cervical Screening Test Results INTRODUCTION This booklet provides you with information to help you better understand your Cervical Screening Test results. Your healthcare
More informationWIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS
Author J. Evans BMS 3 Authoriser A. Bamber Page 1 of 16 WIRRAL UNIVERSITY TEACHING HOSPITAL CYTOLOGY NHS CERVICAL SCREENING PROGRAMME INFORMATION PACK FOR SAMPLE TAKERS Author J. Evans BMS 3 Authoriser
More informationManagement that provides continuity of care for women
Management that provides continuity of care for women If women are diagnosed with reproductive tract infection, prompt treatment should be instituted according to the WHO guidelines. Though it may be preferred
More informationTo further assess abnormalities detected on cervical cytological sample. To guide colposcopically directed biopsy
1 To further assess abnormalities detected on cervical cytological sample To guide colposcopically directed biopsy To exclude invasive disease To aid in outpatient management and treatment of precancerous
More informationCELLULAR PATHOLOGY DEPARTMENT STANDARD OPERATING PROCEDURE INSTRUCTIONS FOR CERVICAL CYTOLOGY SAMPLE TAKERS
Implementation date: October 2006 Page 1 of 7 CELLULAR PATHOLOGY DEPARTMENT STANDARD OPERATING PROCEDURE INSTRUCTIONS FOR CERVICAL CYTOLOGY SAMPLE TAKERS Purpose: This procedure has been written to provide
More informationCervical Cancer : Pap smear
Taking a PAP SMEAR Cervical Cancer : Pap smear George N Papanicolaou introduced cervical cytology in clinical practice in 1940 In 1945, PAP smear was endorsed by American cancer society as an effective
More informationTreatment of Cervical Intraepithelial Neoplasia. Case. How would you manage this woman?
Treatment of Cervical Intraepithelial Neoplasia Karen Smith-McCune Professor, Department of Obstetrics, Gynecology and Reproductive Sciences I have no conflicts of interest Case How would you manage this
More informationGYNAECOLOGICAL CYTOLOGY
The laboratory runs a tour of the department for Practice Nurses on request, as part of their training, explaining the procedures and requirements for Gynae LBC. RECOMMENDED PROTOCOL FOR SMEAR TAKERS Only
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationTO TEST, OR NOT TO TEST? THAT IS THE QUESTION. Cervical screening guide for lesbian and bisexual women in Norfolk and Waveney.
TO TEST, OR NOT TO THAT IS THE QUESTION. Cervical screening guide for lesbian and bisexual women in Norfolk and Waveney. TEST? Every effort has been made to ensure that the information provided is accurate.
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCHAIN Data Analysis. January March 2017 (Quarter 4)
CHAIN Data Analysis January March 2017 (Quarter 4) Headline figures The St Mungo s CHAIN dataset contains statistical information on people sleeping rough in London and is published on a quarterly basis.
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Harrow CCG Profile Version: 3.5 Ref No: P662 Date: March 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy McMeeking,
More informationClinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary
Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary Glossary of Terms Colposcopy is the examination of the cervix, vagina and, in
More informationHPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series
HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%
More informationYour Colposcopy Visit
Introduction Welcome to the colposcopy clinic. This booklet tells you about. The colposcopy examination.. Tests that are done in the colposcopy clinic.. What these tests look for Take a few minutes to
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Hillingdon CCG Profile Version: 3.7 Ref No: P662 Date: February 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Lambeth CCG Profile Version: 3.3 Ref No: P662 Date: March 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy McMeeking,
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates NHS Tower Hamlets CCG Profile Version: 3.5 Ref No: P662 Date: March 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy
More informationSTOP Cancer, before it starts*
About your cervical screening (smear test) Going for screening could save your life. STOP Cancer, before it starts* This leaflet is available in Easy Read, BSL, audio and large print. www.cervicalscreeningwales.wales.nhs.uk
More informationZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust
ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection
More informationWhat Causes Cervical Cancer? Symptoms of Cervical Cancer
Cervical Health Awareness Month is a chance to raise awareness about how women can protect themselves from HPV (human papillomavirus) and cervical cancer. HPV is a very common infection that spreads through
More informationThe Renewed National Cervical Screening Program:
The Renewed National Cervical Screening Program: Key information for Health Professionals Contents: Overview: National Cervical Screening Program... 2 Background: HPV and cervical cancer... 3 HPV testing
More informationInformation on: HPV testing. jostrust.org.uk
Information on: HPV testing jostrust.org.uk HPV testing This booklet covers: What is HPV? How do you get HPV? HPV testing Results of HPV testing Jo s Cervical Cancer Trust 2 What is HPV testing? Human
More informationCervical Screening - The Facts Sgrinio Serfigol - Y Ffeithiau AWARDED FOR EXCELLENCE
Cervical Screening - The Facts Sgrinio Serfigol - Y Ffeithiau AWARDED FOR EXCELLENCE This leaflet tells you about cervical screening. Cervical Screening Wales (CSW) invites all eligible women who live
More informationNew guidelines for HIV testing and areas where wider HIV testing policies should be considered.
New guidelines for HIV testing and areas where wider HIV testing policies should be considered. New guidelines 1 from the British HIV Association (BHIVA), the British Association for Sexual Health and
More informationEfficacy of cervical intrarepithelial neoplasia (CIN)
The Ulster Medical Journal, Volume 72, No. 1, pp. 10-15, May 2003. Efficacy of cervical intrarepithelial neoplasia (CIN) treatment by cold coagulation A Zawislak, J H Price, H R McClelland, R G N Storey,
More informationAnalysis of One- Year Cancer Survival Rates
Analysis of One- Year Cancer Survival Rates Profile Version: 3.6 Ref No: P662 Date: February 2016 Author: PHAST Associates Paul Iggulden, Sarah Seager, Sue Atkinson Commissioner: Andy McMeeking, Team Manager
More informationCERVICAL SCREENING WALES
CERVICAL SCREENING WALES Cervical Screening Wales Audit of Cervical Cancer (CSWACC) National Report 1999-2009 For more information about this report contact: Dr Rose Fox Director Cervical Screening Wales
More information!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationHow invasive cervical cancer audit affects clinical practice
How invasive cervical cancer audit affects clinical practice Referring to NHSCSP and EU guidelines and audits in Southampton and London Amanda Herbert Guy s & St Thomas Foundation NHS Trust How invasive
More informationThe new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
More informationCERVICAL SCREENING WALES CERVICAL SCREENING PROGRAMME, WALES: 2001/02
CERVICAL SCREENING WALES INFORMATION TEAM STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2001/02 For more information about this report contact: Helen Beer, Information Analyst / Manager, Screening
More informationAbout your cervical screening (smear test) Going for screening could save your life.
About your cervical screening (smear test) Going for screening could save your life. STOP Cancer, before it starts This leaflet is available in Easy Read, BSL, audio and large print. www.cervicalscreeningwales.wales.nhs.uk
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationPRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.
More informationCryotherapy has No Place in Colposcopy Practice
Cryotherapy has No Place in Colposcopy Practice No financial disclosures No conflicts of interest ? Precision? Personalized Medicine? Best Evidence Based Practice Prinicipals of Surgical Management CIN1
More informationBREAST CANCER & CERVICAL CANCER SCREENING
BREAST CANCER & CERVICAL CANCER 1 BREAST Cancer WHAT IS BREAST CANCER? Breast cancer starts when cells in the breast begin to grow in an uncontrolled way and build up to form a lump (also known as a tumour).
More informationNHS cervical screening
NHS cervical screening Cervical screening the facts This leaflet tells you about cervical screening. It aims to help you choose whether or not to take part in the NHS Cervical Screening Programme. What
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationReport to Health and Well- Being Board on Childhood Immunisation Programmes in Barnet 14 th September 2017/18
Report to Health and Well- Being Board on Childhood Immunisation Programmes in Barnet 14 th September 2017/18 Report on Section 7a Immunisation Programmes in London Borough of Barnet Prepared by: Amanda
More informationHPV-related papillomatous-condylomatous lesions in female anogenital area
HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)
More informationMalaria in London: Review of imported malaria cases. Data from 2000 to 2012
: Review of imported malaria cases Data from 2000 to 2012 About Public Health England We work with national and local government, industry and the NHS to protect and improve the nation's health and support
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationChildren and Young Peoples Oral Health in Barnet
Appendix A Children and Young People s Oral Health in Barnet Introduction Good oral health is integral to a child s general health and well-being, and affects how children grow, enjoy life, look, speak,
More informationThe society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
More informationIslington JSNA 2010/11 Healthy Eating
Islington JSNA 2010/11 Healthy Eating INTRODUCTION A well-balanced diet is important for good health and involves consuming a wide range of foods, including fruit and vegetables, starchy whole grains,
More information2. CANCER AND CANCER SCREENING
2. CANCER AND CANCER SCREENING INTRODUCTION The incidence of cancer and premature mortality from cancer are higher in Islington compared to the rest of England. Although death rates are reducing, this
More informationPreventing cervical cancer Australia. The Renewed National Cervical Screening Program 2019 Common Questions and Cases
The Renewed National Cervical Screening Program 2019 Common Questions and Cases Preventing cervical cancer Australia - National HPV vaccination program - The National cervical screening program Annabelle
More informationIntroduction to Colposcopy
Introduction to Colposcopy Papanicolaou smear (Pap smear) screening test Colposcopy diagnostic test Introduction to Colposcopy Acetic acid and Lugol s iodine applied Cervix examined under magnification
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationCPC on Cervical Pathology
CPC on Cervical Pathology Dr. W.K. Ng Senior Medical Officer Department of Clinical Pathology Pamela Youde Nethersole Eastern Hospital Cervical Smear: High Grade SIL (CIN III) Cervical Smear: High Grade
More informationWhat is cervical cancer?
What is cervical cancer? The cervix is the bottom part, or neck, of the uterus. Cervical cancer happens when normal cells in the cervix change into abnormal cells, and grow out of control. Most women whose
More informationWhat is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System
What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Manager @ Harris Health System What is a Pap Smear and when is it recommended? Pap smear The Pap smear is a screening
More informationCervical screening: it s best to take the test. Updated guidance
Cervical screening: it s best to take the test Updated guidance This leaflet gives information about cervical screening in Northern Ireland. It will help you to understand why it is important to be screened.
More informationVENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS
VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS OCTOBER 2016 CONTENTS Chair s Foreword: Andrew Gwynne MP 3 Summary of Findings 4 Aims and Objectives 5 Results 7 Discussion
More informationCuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015
Programme Report 2014/2015 Contents Summary points 2 Introduction to the statistics 2014/2015 3 Part 1 Cervical screening activity 3 Programme coverage 4 Laboratory turnaround time 7 Notification of results
More informationManagement of Abnormal Cervical Cytology and Histology
Management of Abnormal Cervical Cytology and Histology Assoc. Prof. Gökhan Tulunay Etlik Zübeyde Hanım Women s Diseases Teaching & Research Hospital Gynecologic Oncology Clinic Universally accepted guideline
More informationPreventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE
Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE DR GARY FENTIMAN, CLINICAL LEADER COLPOSCOPY, N C S P TAKE-HOME LESSONS Vaccination is Primary Prevention for Cervical Cancer Women
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationKC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales
KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales CERVICAL SCREENING WALES STATISTICAL REPORT CERVICAL SCREENING PROGRAMME, WALES: 2012/2013 For more information
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More information#AskAboutAsthma: from vision to reality
#AskAboutAsthma: from vision to reality Dr David Finch Interim Clinical Director Healthy London Partnership Children and Young People s Programme GP and Medical Director (NW London) NHS England 21st November
More informationMINISTRY OF HEALTH. CANCER of the CERVIX and its PREVENTION A FACT BOOK FOR HEALTH WORKERS
MINISTRY OF HEALTH CANCER of the CERVIX and its PREVENTION A FACT BOOK FOR HEALTH WORKERS FACTS ABOUT CERVICAL CANCER 1.0 Introduction The cervix is the lowest portion of a woman s uterus (womb). It is
More informationChallenges for the Lung Cancer Pathway Group
Challenges for the Lung Cancer Pathway Group Liz Sawicka Chair Lung Pathway Group Thoracic Physician and Lung Cancer Lead Princess Royal University Hospital SLHT 2 The Problem - Varied outcome for patients
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationPrimary High Risk HPV Testing with Cytology Triage
Primary High Risk HPV Testing with Cytology Triage NHS Cervical Screening Programme Public Health England leads the NHS Screening Programmes Human papillomavirus (HPV) High risk (HR) HPV is associated
More informationLauren O Sullivan, D.O. February 19, 2015
Lauren O Sullivan, D.O. February 19, 2015 1. Review basics of Pap smear, cervical dysplasia/cancer and HPV infection. 2. Review 2012 updated screening guidelines. 3. Discuss how and where to find updated
More informationZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust
ZedScan Case Study NHS Hospital, UK. ZedScan delivers improvements in clinical performance and more efficient patient management at Sheffield Teaching Hospitals NHS Foundation Trust Increased detection
More informationWOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 0 / 0 / 6 ANY MISSING OR INCOMPLETE TEST RESULTS
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 0/0/0 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationMethods of Obstetrics & Gynecology treatment
Methods of Obstetrics & Gynecology treatment Gynecology is the medical practice dealing with the health of the female reproductive systems (vagina, uterus and ovaries) and the breasts Lector: MD Ganna
More informationLABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14
LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L4 ID LABEL HERE ---> - - - VISIT #: FORM COMPLETED BY: VERSION DATE: 09/5/95 ANY MISSING OR INCOMPLETE TEST RESULTS MUST BE EXPLAINED ON THIS FORM.
More informationInformation for trans people
NHS Screening Programmes Public Health England leads the NHS Screening Programmes About this leaflet This leaflet is for trans (transgender) and non-binary people in England. It tells you about the adult
More informationScreening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationSE Coast Cervical Screening QARC Interim Guidance for laboratories on cervical sample acceptance
SE Coast Cervical ing QARC Interim Guidance for laboratories on cervical sample acceptance List of accepted reasons/categories for sample rejection and inadequate cytology reports in SE Coast Version 6,
More informationName of External Assessment Group (EAG) and project leads
Title of the project Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: a systematic review and economic evaluation Name of External Assessment Group (EAG) and project leads
More information1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal
Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa
More informationVENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS
VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS CANCER, CHEMOTHERAPY AND CLOTS OCTOBER 2016 CONTENTS Chair s Foreword: Andrew Gwynne MP 3 Summary of Findings 4 Aims and Objectives 5 Results 7 Discussion
More information